This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Botox at the Center of Recent Healthcare M&A Flurry

04/24/14 - 11:07 AM EDT

How wrinkle reduction is at the crux of the recent M&A frenzy....

READ FULL POST

Is the robust IPO market affecting the broader indices?

04/10/14 - 03:53 PM EDT

There has been a lot of debate of late about whether some of the pain in the so-called momentum names in the last month has something to do with growth money coming into the IPO space...

READ FULL POST

The Momentum Tell and the Yellen Timeline

04/10/14 - 02:47 PM EDT

Talk about whiplash. Yesterday's surge upward was met today with, well, a selloff. So, what gives? What's happening here.

READ FULL POST

Under Armour is cheap! (yes, I said cheap)

03/27/14 - 06:26 PM EDT

This junior growth name still has much room to run based on market potential and new roll-outs.

READ FULL POST

FedEx Corp is a Buy

03/19/14 - 01:58 PM EDT

Even after a lackluster quarter, future remains bright for FedEx

READ FULL POST

Tech in Transition: The Winners

03/19/14 - 11:01 AM EDT

Transitions, if believed, allow investors to look through short term disruption

READ FULL POST

Spin = Win

03/18/14 - 07:41 PM EDT

The news that Hertz is spinning off its equipment rental business reinforces why it remains the best positioned in the car rental group

READ FULL POST

The Lesson of Allergan

03/18/14 - 07:17 PM EDT

Just over one year ago, when Allergan stood at about $115, worries abounded, causing the stock to drop to the low $80s by the middle of 2013, as the overall equity market continued to roar. This underperformance spooked many investors, but that low was a huge opportunity, as the stock has posted a stellar run ever since, now at new highs at over $130. I bring this up now because many are talking about a bubble in biotech, particularly given surges from recent IPOs.

READ FULL POST

The All Important Jobs Number

03/07/14 - 08:34 AM EST

All eyes are on the non-farm payroll numbers this morning, but take a look at some bizarre things happening in the U.S. economy right now

READ FULL POST

Hidden Camera Captures Debate Over Costco's Future

03/06/14 - 08:43 AM EST

Costco is down this morning on a disappointing report. Check out this hidden camera capturing a debate over Costco's drivers

READ FULL POST

Nicole Urken is Research Director of Mad Money and Jim Cramer's researcher at TheStreet. Nicole analyzes stocks and develops a strategic macro outlook, which she incorporates into segment ideas for CNBC's "Mad Money." Nicole also supports Jim's other endeavors including "Squawk on the Street," RealMoney.com, and his latest best-selling book "Get Rich Carefully."

Previously, she worked as an investment banking analyst for the Industrials Group in Goldman Sachs' New York office. Born and raised in Princeton, New Jersey, Nicole graduated with honors from Harvard College, where she served as executive editor of The Harvard Crimson.

Markets

DOW 17,018.88 -20.61 -0.12%
S&P 500 1,989.44 -2.93 -0.15%
NASDAQ 4,540.0160 +7.9120 0.17%

Nicole's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs